imuran 50mg vial solution for injection
aspen - azathioprine - solution for injection - 50 mg
imuran 50 mg (orifarm) film-coat. tabl.
orifarm a.s. - azathioprine 50 mg - film-coated tablet - azathioprine
imuran 50 mg (pi pharma) film-coat. tabl.
pi pharma sa-nv - azathioprine 50 mg - film-coated tablet - azathioprine
imuran 50 mg inj. sol. (pwdr.) i.v. vial
aspen pharma trading ltd. - azathioprine 50 mg - powder for solution for injection - azathioprine
imuran 50 mg tablet
n/a; importer: aspen philippines inc.; distributor: n/a - azathioprine - tablet - 50 mg
imuran 50mg tablets
beta healthcare international limited plot no. 209/6554, mogadishu road off lunga lunga - azathioprine - tablet - 50mg - other immunosuppressants
imuran 25mg
pharmacare limited - azathioprine 25 mg - tablet - 25mg azathioprine
imuran
pharmacare limited - azathioprine 50 mg - tablet - 50mg azathioprine
humira- adalimumab
a-s medication solutions - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - humira is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. humira can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). humira is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. humira can be used alone or in combination with methotrexate. humira is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. humira can be used alone or in combination with non-biologic dmards. humira is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. humira is indicated for reducing signs and symptoms and indu
highlights of prescribing information
kadmon pharmaceuticals, llc - ribavirin (unii: 49717awg6k) (ribavirin - unii:49717awg6k) - ribavirin 200 mg - ribasphere® (ribavirin capsules usp) in combination with interferon alfa-2b (pegylated and nonpegylated) is indicated for the treatment of chronic hepatitis c (chc) in patients 3 years of age and older with compensated liver disease [see warnings and precautions (5.9, 5.10) , and use in specific populations (8.4) ]. the following points should be considered when initiating ribasphere combination therapy with peginterferon alfa-2b or interferon alfa-2b: ribasphere combination therapy is contraindicated in: teratogenic effects pregnancy category x [see contraindications (4), warnings and precautions (5.1), and nonclinical toxicology (13.1) ]. treatment and post-treatment: potential risk to the fetus: ribavirin is known to accumulate in intracellular components from where it is cleared very slowly. it is not known whether ribavirin contained in sperm will exert a potential teratogenic effect upon fertilization of the ova. in a study in rats, it was concluded that dominant lethality was not induced by ribavirin